摘要
先前的研究已经表明,轻度认知障碍(MCI)可能反映神经退行性疾病的早期阶段,如阿尔茨海默病(AD)。假说是在澳大利亚影像学、生物标志物和生活方式(AIBL)关于衰老的标志研究中,细胞角蛋白(CK)14表达在独立的颊粘膜中可以作为生物标志物去识别个体轻度认知障碍或阿尔兹海默病。使用免疫荧光技术视觉评估颊粘膜细胞CK14表达。基底颊粘膜细胞CK14表达频率MC组(P = 0.0002)和AD组(P < 0.05)组明显低于对照组。受试者工作特性曲线(ROC)表明CK14表达和曲线下面积(AUC),MCI组(P < 0.0001)为0.899;AD组(P = 0.004)为0.772。CK14表达数据与血浆同型半胱氨酸浓度结合时,AUC会进一步提高,MCI 组(P=0.0001)为0.932;AD组(P = 0.004)为0.788。与控制非APOE ε4载体相比对照组中APOE ε4载体的 CK14表达下降21%,但差异无统计学意义。在这个试验性研究中,颊粘膜细胞CK14表达的变化证明,其作为一个潜在的生物标志物以识别个体MCI的发展并最终导致AD风险的可行性。这些有前景的结果需要在更大的AIBL同类研究亚型和其他同类神经退行性疾病研究中重复观察,以确定AD变化的特异性。
关键词: AIBL,阿尔茨海默症,颊粘膜细胞,细胞角蛋白,同型半胱氨酸,免疫荧光
Current Alzheimer Research
Title:Buccal Cell Cytokeratin 14 Identifies Mild Cognitive Impairment and Alzheimer’ s Disease in the AIBL Study of Aging
Volume: 12 Issue: 3
Author(s): Wayne R. Leifert, Jannatul Ferdoush Tuli, Maxime Francois, Tori Nguyen, Alan Rembach, Rebecca L. Rumble, Stephanie Rainey-Smith,
Affiliation:
关键词: AIBL,阿尔茨海默症,颊粘膜细胞,细胞角蛋白,同型半胱氨酸,免疫荧光
摘要: Previous studies have suggested that mild cognitive impairment (MCI) may be reflective of the early stages of neurodegenerative disorders such as Alzheimer’s disease (AD). The hypothesis was that cytokeratin (CK) 14 expression can be used as a biomarker in isolated buccal mucosa to identify individuals with MCI or AD from the Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study of aging. Visual assessment of buccal cell CK14 expression was carried out using immunofluorescence techniques. The frequency of basal buccal cells expressing CK14 was significantly lower in the MCI (P=0.0002) and AD (P<0.05) groups compared with the control group. Receiver-operating characteristic (ROC) curves were carried out for CK14 expression and yielded an area under the curve (AUC) of 0.899 for the MCI (P<0.0001) group and 0.772 for the AD (P=0.004) group. When the CK14 expression data were combined with plasma homocysteine concentration, the AUC was further improved to 0.932 and 0.788 for the MCI (P=0.0001) and AD (P=0.004) groups, respectively. APOE ε4 carriers in the control group had 21% lower CK14 expression compared with control non APOE ε4 carriers, however this difference was not statistically significant. The changes in the buccal cell CK14 expression observed in this pilot study could prove useful as a potential biomarker in identifying individuals with an increased risk of developing MCI and eventually AD. These promising results need to be replicated in a larger subset of the AIBL cohort and in cohorts of other neurodegenerative disorders to determine changes specific to AD.
Export Options
About this article
Cite this article as:
Wayne R. Leifert, Jannatul Ferdoush Tuli, Maxime Francois, Tori Nguyen, Alan Rembach, Rebecca L. Rumble, Stephanie Rainey-Smith, , Buccal Cell Cytokeratin 14 Identifies Mild Cognitive Impairment and Alzheimer’ s Disease in the AIBL Study of Aging, Current Alzheimer Research 2015; 12 (3) . https://dx.doi.org/10.2174/1567205012666150302154650
DOI https://dx.doi.org/10.2174/1567205012666150302154650 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Does Human Alpha-Synuclein Behave Like Prions?
CNS & Neurological Disorders - Drug Targets Progranulin Regulates Inflammation and Tumor
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Synopsis on Managment Strategies for Neurodegenerative Disorders: Challenges from Bench to Bedside in Successful Drug Discovery and Development
Current Topics in Medicinal Chemistry Mesenchymal Stromal Cells from Umbilical Cord Blood
Current Stem Cell Research & Therapy Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer’s Disease: Implications for the Treatment
Current Genomics Therapeutic and Mechanistic Effects of Curcumin in Huntington’s Disease
Current Neuropharmacology Endogenous and Exogenous CNS Derived Stem / Progenitor Cell Approaches for Neurotrauma
Current Drug Targets Recent Advances on the Role of Neurogenesis in the Adult Brain: Therapeutic Potential in Parkinson's and Alzheimer's Diseases
CNS & Neurological Disorders - Drug Targets The Applications of Pharmacogenomics to Neurological Disorders
Current Molecular Medicine Lipids at the Cross-road of Autoimmunity in Multiple Sclerosis
Current Medicinal Chemistry The Endocannabinoid System May Modulate Sleep Disorders in Aging
Current Neuropharmacology One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke
Current Neuropharmacology Genetics and Bioenergetics of Mitochondria Influencing the Etiology and Pharmacology of Steroidal Hormones
Current Pharmacogenomics Challenges of Gene Therapy for Neurodegenerative Disorders
Current Gene Therapy Dissecting the Mechanisms of Thrombogenesis and Atherosclerosis for Neurodegenerative Disorders
Current Neurovascular Research Microglial Senescence
CNS & Neurological Disorders - Drug Targets Preclinical Safety and Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified Activated Protein C for Ischemic Stroke
Current Pharmaceutical Design Influence of Lithium Treatment on GDNF Serum and CSF Concentrations in Patients with Early Alzheimers Disease
Current Alzheimer Research Alzheimer’s and Type 2 Diabetes Treatment via Common Enzyme Targeting
CNS & Neurological Disorders - Drug Targets ADAM Proteases: Protective Role in Alzheimers and Prion Diseases ?
Current Alzheimer Research